ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A

ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A

Mutations in the BAF SWI/SNF complex subunits are frequent in cancers but selective therapeutic approaches are not available yet. Here, the authors demonstrate that defects ofARID1Aand other subunits sensitizes cancer cells to the DNA checkpoint kinase inhibitor ATR in a synthetic lethal manner.

Saved in:
Bibliographic Details
Main Authors: Chris T. Williamson, Rowan Miller, Helen N. Pemberton, Samuel E. Jones, James Campbell, Asha Konde, Nicholas Badham, Rumana Rafiq, Rachel Brough, Aditi Gulati, Colm J. Ryan, Jeff Francis, Peter B. Vermulen, Andrew R. Reynolds, Philip M. Reaper, John R. Pollard, Alan Ashworth, Christopher J. Lord
Format: article
Language:EN
Published: Nature Portfolio 2016
Subjects:
Science
Q
Online Access:https://doaj.org/article/e641244f3cf24d9e87d1e6540b5b48bf
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doaj.org/article/e641244f3cf24d9e87d1e6540b5b48bf

Similar Items